Adiponectin, Resistin and Leptin: Possible Markers of Metabolic Syndrome

Abstract

The metabolic syndrome is a major and escalating public-health and clinical challenge worldwide. Most studies show that the MS is associated with an approximate doubling of cardiovascular disease risk and a 5-fold increased risk for incident type 2 diabetes mellitus. Adipose tissue is actively involved in metabolic processes and secretes adiposederived factors named adipokines. Adipokines have been linked to the pathogenesis of MS and its comorbidities. This study was established to estimate the use of adipocytokines as early markers of metabolic disorders. 70 participants were enrolled into the study, divided into two groups depending on presence of MS. It has been demonstrated that plasma adiponectin concentrations correlate negatively with HOMA-IR, the relationship of blood lipid disorders and level of adiponectin were shown in MS patients. Resistin levels rise in parallel with increase in BMI in overweight and obese MS patients; significant correlation between elevated resistin levels and HOMA-IR index were shown. Leptin levels were significantly higher in patients with metabolic syndrome.